Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy

Drug Allergy Clinical Trial

Official title:
Improved Basophil Activation Test (BAT) in the Diagnostics of IgE-mediated Drug Allergy

Status Enrolling by invitation

Clinical Trial Summary

Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs).

Clinical Trial Description

Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). Among commonly used CD63/CD203c markers, newly proposed molecules, such as CD69, CD107a, CD164, CD13, CD11b and CD300a will be assayed. Results obtained together with the other clinical data will be used to calculate sensitivity and specificity of the method. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03164044
Study type	Observational
Source	The Republican Research and Practical Center for Epidemiology and Microbiology
Contact
Status	Enrolling by invitation
Phase
Start date	January 3, 2017
Completion date	June 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05706246` - Perioperative Hypersensitivity in Children	N/A
Recruiting	`NCT04920721` - Retrospective Study of Immediate Hypersensitivity (IHS) Reactions to Platinum Salts in the University Hospital of Nancy
Completed	`NCT02118987` - Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization	Phase 1
Completed	`NCT02094638` - Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study	N/A
Completed	`NCT03784482` - Multiple Drug Hypersensitivity Syndrome
Recruiting	`NCT05820802` - High Dimensional Analysis of Immune Cells in Pediatric Patients